Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Significance: TNF is known to play an important role in various neurodegenerative diseases. However, anti-TNF therapeutics failed in clinical trials of neurodegenerative diseases. This failure is most likely due to antithetic effects of the TNF receptors in the central nervous system, whereby TNFR1 promotes inflammatory degeneration and TNFR2 neuroprotection. Here we show that novel TNFR-selective therapeutics, i.e., a TNFR1 antagonist and a TNFR2 agonist, block neuroinflammation and promote neuronal survival in a mouse model of neurodegeneration related to Alzheimer disease as well as other neurodegenerative diseases. Most important, neuroprotection mediated by the TNFR1 antagonist is abrogated by simultaneous blockade of TNFR2 activation, revealing that neuroprotection requires TNFR2 signaling and uncover why anti-TNF drugs failed in treatment of neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,440
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
CellProfiler: image analysis software for identifying and quantifying cell phenotypes
Carpenter, A. E., Jones, T. R., Lamprecht, M. R., Clarke, C., Kang, I. H., Friman, O., Guertin, D. A., Chang, J. H., Lindquist, R. A., Moffat, J., et al. (2006) · Genome Biology · doi:10.1186/gb-2006-7-10-r100 · Cited by 5,157
Signalling pathways of the TNF superfamily: a double-edged sword
Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793 · cited 1×
“T necrosis factor (TNF) is a master proinflammatory cytokine that plays an important role in the initiation and orchestration of immunity and inflammation (1, 2).”
BackgroundTumor necrosis factor signaling
Wajant, H., Pfizenmaier, K., & Scheurich, P. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401189 · Cited by 2,359
Self-citationGrell, M., Douni, E., Wajant, H., Löhden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90192-2 · Cited by 1,325 · cited 1×
“Interestingly, induction of cell death was not enhanced by addition of the cross-linking TNFR2-specific monoclonal antibody 80M2, which in concert with soluble TNF is able to mimic the action of tmTNF (11, 28).”
BackgroundSelf-citationDurocher, Y. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.2.e9 · Cited by 1,037
TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) · Neurology · doi:10.1212/wnl.53.3.457 · Cited by 1,017
TNFα promotes proliferation of oligodendrocyte progenitors and remyelination
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., & Ting, J. P.-Y. (2001) · Nature Neuroscience · doi:10.1038/nn738 · Cited by 1,012
Donnelly, D. J., & Popovich, P. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.06.009 · Cited by 995 · cited 1×
“these glutamate receptors may lead to progressive neuronal cell death, which is a hallmark of acute and chronic neurological diseases (17).”
BackgroundMcCoy, M. K., & Tansey, M. G. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-45 · Cited by 847
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794 · cited 1×
“Thus, antibodies engineered to be actively transported via BBB have been developed that were shown to be beneficial for the treatment of Alzheimer’s disease (48, 49).”
BackgroundInterrelation of Oxidative Stress and Inflammation in Neurodegenerative Disease: Role of TNF
Fischer, R., & Maier, O. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/610813 · Cited by 731 · cited 2×
“Biochem Biophys Res Commun 440(2):336–341.”
BackgroundSelf-citationParsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 707
Fontaine, V., Mohand-Said, S., Hanoteau, N., Fuchs, C., Pfizenmaier, K., & Eisel, U. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-j0001.2002 · Cited by 585
Self-citationSource specificity of early calcium neurotoxicity in cultured embryonic spinal neurons
Tymianski, M., Charlton, M., Carlen, P., & Tator, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-05-02085.1993 · Cited by 567 · cited 1×
“Exacerbated activation of glutamate receptor-coupled calcium channels and subsequent increase in intracellular calcium concentrations ([Ca]i), followed by sustained disturbances in the [Ca ]i homeostasis, are established hallmarks of neuronal cell death in acute and chronic neurological diseases (29, 30).”
BackgroundChen, X., Bäumel, M., Männel, D. N., Howard, O. M. Z., & Oppenheim, J. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.154 · Cited by 548
Benzodiazepine impairs and β-carboline enhances performance in learning and memory tasks
Venault, P., Chapouthier, G., de Carvalho, L. P., Simiand, J., Morre, M., Dodd, R. H., & Rossier, J. (1986) · Nature · doi:10.1038/321864a0 · Cited by 503
TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects
Probert, L. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.038 · Cited by 495 · cited 1×
“This dual role of TNF signaling becomes particularly obvious in the central nervous system (5, 6).”
BackgroundMarchetti, L., Klein, M., Schlett, K., Pfizenmaier, K., & Eisel, U. L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311766200 · Cited by 427
Self-citationThayer, S. A., & Miller, R. J. (1990) · The Journal of Physiology · doi:10.1113/jphysiol.1990.sp018094 · Cited by 403 · cited 1×
“Exacerbated activation of glutamate receptor-coupled calcium channels and subsequent increase in intracellular calcium concentrations ([Ca]i), followed by sustained disturbances in the [Ca ]i homeostasis, are established hallmarks of neuronal cell death in acute and chronic neurological diseases (29, 30).”
BackgroundCortical projection patterns of the medial septum‐diagonal band complex
Gaykema, R. P. A., Luiten, P. G. M., Nyakas, C., & Traber, J. (1990) · Journal of Comparative Neurology · doi:10.1002/cne.902930109 · Cited by 387
Self-citationTargeted disruption of the MHC class II Aa gene in C57BL/6 mice
Köntgen, F., Süss, G., Stewart, C., Steinmetz, M., & Bluethmann, H. (1993) · International Immunology · doi:10.1093/intimm/5.8.957 · Cited by 364
Chen, X., Subleski, J. J., Kopf, H., Howard, O. M. Z., Männel, D. N., & Oppenheim, J. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.6467 · Cited by 335
Chen, X., Wu, X., Zhou, Q., Howard, O. M. Z., Netea, M. G., & Oppenheim, J. J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202659 · Cited by 293
Fotin-Mleczek, M., Henkler, F., Samel, D., Reichwein, M., Hausser, A., Parmryd, I., Scheurich, P., Schmid, J. A., & Wajant, H. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.13.2757 · Cited by 284
A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
Atwal, J. K., Chen, Y., Chiu, C., Mortensen, D. L., Meilandt, W. J., Liu, Y., Heise, C. E., Hoyte, K., Luk, W., Lu, Y., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002254 · Cited by 274 · cited 1×
“Thus, antibodies engineered to be actively transported via BBB have been developed that were shown to be beneficial for the treatment of Alzheimer’s disease (48, 49).”
BackgroundHarkany, T., Ábrahám, I., Timmerman, W., Laskay, G., Tóth, B., Sasvári, M., Kónya, C., Sebens, J. B., Korf, J., Nyakas, C., et al. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00164.x · Cited by 273
Self-citationTNFα Transport across the Blood–Brain Barrier Is Abolished in Receptor Knockout Mice
Pan, W., & Kastin, A. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7871 · Cited by 210
Brambilla, R., Ashbaugh, J. J., Magliozzi, R., Dellarole, A., Karmally, S., Szymkowski, D. E., & Bethea, J. R. (2011) · Brain · doi:10.1093/brain/awr199 · Cited by 210
Loetscher, H., Stueber, D., Banner, D., Mackay, F., & Lesslauer, W. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74322-1 · Cited by 208 · cited 4×
“1E), verifying that EHD2–scTNFR2 had lost affinity for TNFR1 due to the mutations D143N/A145R.”
BackgroundInfluentialChen, X., Subleski, J. J., Hamano, R., Howard, O. M. Z., Wiltrout, R. H., & Oppenheim, J. J. (2010) · European Journal of Immunology · doi:10.1002/eji.200940022 · Cited by 207
Weiss, T., Grell, M., Hessabi, B., Bourteele, S., Müller, G., Scheurich, P., & Wajant, H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.5.2398 · Cited by 185
Homogeneous Expansion of Human T-Regulatory Cells Via Tumor Necrosis Factor Receptor 2
Okubo, Y., Mera, T., Wang, L., & Faustman, D. L. (2013) · Scientific Reports · doi:10.1038/srep03153 · Cited by 170
Chen, X., Hamano, R., Subleski, J. J., Hurwitz, A. A., Howard, O. M. Z., & Oppenheim, J. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903548 · Cited by 143
Patel, J. R., Williams, J. L., Muccigrosso, M. M., Liu, L., Sun, T., Rubin, J. B., & Klein, R. S. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1034-0 · Cited by 134 · cited 2×
“In addition to the potential therapeutic use of TNFR1specific antagonistic antibodies, TNFR2-selective agonists seem to be particularly suitable to treat inflammatory, demyelinating diseases, because next to the direct neuroprotective effects shown in this report, data from different laboratories outline that TNFR2 is…”
BackgroundA TNF Receptor 2 Selective Agonist Rescues Human Neurons from Oxidative Stress-Induced Cell Death
Fischer, R., Maier, O., Siegemund, M., Wajant, H., Scheurich, P., & Pfizenmaier, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027621 · Cited by 129 · cited 3×
“Efficient activation of TNFR2 requires receptor oligomerization by the membrane form of TNF (tmTNF) or oligomerized soluble forms of tmTNF mimicking receptor activation via tmTNF (11, 25) such as a TNFR2-selective TNF mutein, fused to the trimerization domain tenascin C (TNC–scTNFR2) recently developed by the authors…”
BackgroundSelf-citationTNF-α: An Activator of CD4+FoxP3+TNFR2+ Regulatory T Cells
Chen, X., & Oppenheim, J. J. (2010) · Current directions in autoimmunity · doi:10.1159/000289201 · Cited by 126
Fischer, R., Wajant, H., Kontermann, R., Pfizenmaier, K., & Maier, O. (2014) · Glia · doi:10.1002/glia.22605 · Cited by 124 · cited 2×
“In addition to the potential therapeutic use of TNFR1specific antagonistic antibodies, TNFR2-selective agonists seem to be particularly suitable to treat inflammatory, demyelinating diseases, because next to the direct neuroprotective effects shown in this report, data from different laboratories outline that TNFR2 is…”
BackgroundSelf-citationTR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis.
Grell, M., Scheurich, P., Meager, A., & Pfizenmaier, K. (1993) · PubMed · Cited by 115
Self-citationTNF pathophysiology in murine models of chronic inflammation and autoimmunity
Kollias, G. A. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.01.002 · Cited by 114
Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy
Fischer, R., Kontermann, R. E., & Maier, O. (2015) · Antibodies · doi:10.3390/antib4010048 · Cited by 99
Self-citationTaoufik, E., Tseveleki, V., Chu, S. Y., Tselios, T., Karin, M., Lassmann, H., Szymkowski, D. E., & Probert, L. (2011) · Brain · doi:10.1093/brain/awr203 · Cited by 94
Brain damage in a mouse model of global cerebral ischemia
Olsson, T., Wieloch, T., & Smith, M.-L. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03014-2 · Cited by 87 · cited 1×
“Consequently, NMDA receptor antagonists such as dizocilpine (MK-801) or memantine were developed and revealed neuroprotective effects against ischemia-induced neuronal death in vitro and ischemic brain damage in vivo (18, 19).”
BackgroundDolga, A. M., Granic, I., Blank, T., Knaus, H., Spiess, J., Luiten, P. G. M., Eisel, U. L. M., & Nijholt, I. M. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05701.x · Cited by 86
Self-citationAntibody-Mediated Inhibition of TNFR1 Attenuates Disease in a Mouse Model of Multiple Sclerosis
Williams, S. K., Maier, O., Fischer, R., Fairless, R., Hochmeister, S., Stojic, A., Pick, L., Haar, D., Musiol, S., Storch, M. K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090117 · Cited by 86 · cited 2×
“Indeed, the reported therapeutic activity of ATROSAB in EAE models (40) supports this reasoning.”
BackgroundSelf-citationNovrup, H. G., Bracchi-Ricard, V. C., Ellman, D. G., Ricard, J., Jain, A., Runko, E., Lyck, L., Yli-Karjanmaa, M., Szymkowski, D. E., Pearse, D. D., et al. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0159-6 · Cited by 76 · cited 1×
“However, preclinical studies in the experimental autoimmune encephalomyelitis (EAE) model (36–38) or a mouse model of spinal cord injury (39) revealed that selective neutralization of sTNF/TNFR1 signaling is neuroprotective.”
BackgroundATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody
Zettlitz, K. A., Lorenz, V., Landauer, K., Münkel, S., Herrmann, A., Scheurich, P., Pfizenmaier, K., & Kontermann, R. E. (2010) · mAbs · doi:10.4161/mabs.2.6.13583 · Cited by 68 · cited 1×
“We here report on the therapeutic activity of the human TNFR1-selective antagonist ATROSAB (21, 22) and a human TNFR2 selective agonist (EHD2-scTNFR2) in in vitro and in vivo models of excitotoxic brain damage (23, 24) using humanized TNFR1 and TNFR2 knock-in mice.”
BackgroundSelf-citationTNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress
Maier, O., Fischer, R., Agresti, C., & Pfizenmaier, K. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.09.083 · Cited by 64 · cited 1×
“Specific activation of TNFR2 rescues neurons (11) and oligodendrocytes (12) from oxidative stress and promotes oligodendrocyte differentiation and myelination (13, 14).”
BackgroundSelf-citationLovastatin Induces Neuroprotection Through Tumor Necrosis Factor Receptor 2 Signaling Pathways
Dolga, A. M., Nijholt, I. M., Ostroveanu, A., ten Bosch, Q. A., Luiten, P. G. M., & Eisel, U. L. M. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13201 · Cited by 63
Self-citationLuiten, P. G. M., Douma, B. R. K., van der Zee, E. A., & Nyakas, C. J. (1995) · Neurodegeneration · doi:10.1016/1055-8330(95)90020-9 · Cited by 63
Self-citationDolga, A. M., Terpolilli, N. A., Kepura, F., Nijholt, I. M., Knaus, H.-G., D’Orsi, B., Prehn, J. H. M., Eisel, U. L. M., Plant, T., Plesnila, N., et al. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.30 · Cited by 61 · cited 1×
“Interestingly, activation of potassium intermediate/small conductance calciumactivated channel KCa2 prevented [Ca ]i deregulation and reduced neuronal death following glutamate toxicity and cerebral ischemia (31).”
BackgroundSelf-citationDong, Y., Dekens, D. W., Deyn, P. P. D., Naudé, P. J. W., & Eisel, U. L. M. (2015) · Antibodies · doi:10.3390/antib4040369 · Cited by 56
Self-citationAntagonistic TNF Receptor One-Specific Antibody (ATROSAB): Receptor Binding and In Vitro Bioactivity
Richter, F., Liebig, T., Guenzi, E., Herrmann, A., Scheurich, P., Pfizenmaier, K., & Kontermann, R. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072156 · Cited by 45 · cited 1×
“We here report on the therapeutic activity of the human TNFR1-selective antagonist ATROSAB (21, 22) and a human TNFR2 selective agonist (EHD2-scTNFR2) in in vitro and in vivo models of excitotoxic brain damage (23, 24) using humanized TNFR1 and TNFR2 knock-in mice.”
BackgroundSelf-citationZhang, L., Mitani, A., Yanase, H., & Kataoka, K. (1997) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19970215)47:4<440::aid-jnr9>3.0.co;2-e · Cited by 44
Granic, I., Nyakas, C. J., Luiten, P. G. M., Eisel, U. L. M., Halmy, L. G., Groß, G., Schoemaker, H., Möller, A., & Nimmrich, V. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.013 · Cited by 42 · cited 1×
“We here report on the therapeutic activity of the human TNFR1-selective antagonist ATROSAB (21, 22) and a human TNFR2 selective agonist (EHD2-scTNFR2) in in vitro and in vivo models of excitotoxic brain damage (23, 24) using humanized TNFR1 and TNFR2 knock-in mice.”
BackgroundSelf-citationDolga, A. M., Granic, I., Nijholt, I. M., Nyakas, C. J., van der Zee, E. A., Luiten, P. G. M., & Eisel, U. L. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1052 · Cited by 37
Self-citationEvangelidou, M., Καραμίτα, Μ., Vamvakas, S. M., Szymkowski, D. E., & Probert, L. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1300633 · Cited by 27
Harkany, T., Grosche, J., Mulder, J., Horváth, K., Keijser, J. N., Hortobágyi, T., Luiten, P. G. M., & Härtig, W. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00443-2 · Cited by 25
Cited by
The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond
Dostert, C., Grusdat, M., Letellier, E., & Brenner, D. (2019) · Physiological Reviews · doi:10.1152/physrev.00045.2017 · Cited by 498
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target
Mifflin, L., Ofengeim, D., & Yuan, J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0071-y · Cited by 479
Post-stroke inflammation—target or tool for therapy?
Lambertsen, K. L., Finsen, B., & Clausen, B. H. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1930-z · Cited by 465
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study
Zhang, B., Wang, H. E., Bai, Y.-M., Tsai, S.-J., Su, T.-P., Chen, T.-J., Wang, Y.-P., & Chen, M.-H. (2021) · Gut · doi:10.1136/gutjnl-2020-320789 · Cited by 292
Metadata
- Authors
- Dong, Y., Fischer, R., Naudé, P. J. W., Maier, O., Nyakas, C., Duffey, M., Van der Zee, E. A., Dekens, D., Douwenga, W., Herrmann, A., Guenzi, E., Kontermann, R. E., Pfizenmaier, K., & Eisel, U. L. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2016-10-10
- Volume
- 113
- Issue
- 43
- Pages
- 12304-12309
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2531113777
- Cited by
- 166
- References
- 60
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.